Professional Documents
Culture Documents
Outline
Monoclonal antibody production Protein A free antibody production Plasmid isolation Some examples of Vaccine purification
Page 2
Generic name
Alemtuzumab Trastuzumab Gemtuzumab ozogamicin Muromonab-CD3 Infliximab Abciximab Rituximab Basiliximab Palivizumab Daclizumab Ibritumomab tiuxetan
Dose
30 mg 440 mg 5 mg 5 mg 100 mg 10 mg 100 mg 20 mg 50 mg 25 mg 3.2 mg
Page 3
1 02
0x 0
capture
Because each product differs widely, platform technologies help to solve the bottleneck
Page 5
is not possible
Page 6
Platform Technology:
Predetermined
Set of resins & buffers & salts / load capacity / loading flow rate Bed height (certain column diameters) Column regeneration & storage Type and volume of equilibration post load wash buffers
Pre-clinical
Phase I Phase II
Phase III
1996
1997
1998
1999
2000
2001
US 3K approval
Page 8
HerceptinTM Cell removal Protein A Affinity chromatography Virus inactivation Cation exchange Anion exchange Hydrophobic interaction Size exclusion chromatography Virus clearance Sterile filtration 1 2 3 4 5 6
Rituxan 1 2 3 5 4
MabCampathTM 1 2 3 4
SynagisTM 1
RemicadeTM 1 2
SimulectTM 1 2 3 5 4
4 3 2&6
3 4 6&7
5 7 6 7 6 7
8 5&6 9 5 8 6 7
The numbers indicate the position of the step within the dsp processing scheme.
modified acc. to Sommerfeld & Strube, Chemical Engineering and Prosessing 44, 1123-1137, 2005
Page 9
capture
Prot. A binding capacity ~ 35 g/L; 2 m column, bed height 15 cm IEX binding capacity AEX ~ 40-100 g/L, AEX 1.5 m , bed height 25 cm
CEX
intermediate
HIC HIC
polishing
Pure antibody
Page 11
Flow rate during packing 8.5 L/min, 347 cm/hr, conditioned at 20 psi
Page 12
UF/DF
Polishing
rProt A
Anion exchanger (binding mode)
88% purity Reduction of incomplete Ab to <2% Reduction of aggregates to <2.7% Removal of high pI isoforms
Limitations of Protein A:
High resin cost Residual Protein A impurity Sanitisation under harsh conditions results in loss of capacity Acid elution may result in aggregation for some antibodies
Prot A
Source: Poster WilBio 2006, Thousand Oaks, Packed Bed Hydrodynamics of a Highly Charged Ion Exchange Resin at Ionic Strength Extremes; Aaron Noyes et al.
Cation exchanger
Benzonase
Prot A
Nanofiltration/Low pH inactivation
Anion exchanger
UF/DF
Sterile filtration
Pure antibody
Page 16
TFF
Platform
CEX (40-100mg/ml)
recovery: 85-95%
viral inactivation viral inactivation
Virus filter
Suppl. to Biopharm International, February 2007
Page 17
Current Platform
Upstream CHO Fed-batch > 3 g/L Harvest by DepthF
Downstream
Only Protein A processes 3 chromatography steps Multiple in-process TFFs IV formulations
Alahari Arunakumari, Paris, 24th & 25th April 2007
Downstream
Mainly Non-ProteinA 2 chromatography steps No in-process TFFs IV, ID, and subQ formulations
BioProcess International European Conference and Exhibition, Page 18
Protein A softgel
VI UF IEX UF VRF
IEX
UF
Protein A rigid
VI UF
UF VRF IEX UF
for increased productivity rigid media are advantageous Higher bed height = more column capacity = less re-cycling
From: An evaluation of Protein A and Non-Protein A methods for the recovery of monoclonal antibodies and considerations for process scale-up by Martin Smith, LONZA, Presented atScaling-up of Biopharmaceutical Products, 26/27thJanuary 2004, The Grand, Amsterdam
Page 19
IEX
pH FF ,
ro se
XL ,p H
FF ,
pH
ro se
ro se
Se ph a
Se ph a
SP
SP
Se ph a
SP
SP
Se ph a
ro se
ro se
Page 20
Fractogel
SO3 (S)
2500
2000
1500 40.0
1000
20.0 500
4.5
0 0
X1
X2 50
X31A1 1A11 1B41C5 1C6-1F6 1F5 1G4X4 Waste4.2 100 150 min
0 0
X1
X2
X31A11A11 1C5 1B4 1E3 1E12 1G5X4 Waste 1F4 50 100 min
pH 5
Page 21
mAU mAU
3500
3000 3000
2500
2000
2000
1500
1000
1000
500
mAb pool
0 0 50 100 150 200 250 ml 0 0 50 100
mAb pool
150
200
250
ml
CEX 1
CEX 2
Sharp elution is preferred
Page 22
Page 23
24
Page 24
Parameters to be investigated
Parameter
Binding capacity Yield Biological activity Purity
plate
static (yes) yes hcp
column
dynamic yes yes
Prot. A leakage aggregates Washing conditions cycle number (yes) no yes yes
Page 25
Advantage: Many conditions can be tested Disadvantage: Additional characterization of many samples is laborious Static vs dynamic binding capacity Column effects Scale-dependent parameters
Page 26
SEC Conditioning*
*Adjustment for binding on HIC (AS)
Improved downstream process for the production of plasmid DNA for gene therapy, Jochen Urthaler, Wolfgang Buchinger and Roman Necina; Acta Biochimica Polonica Vol. 52 No. 3/2005, 703711
Page 27
Purified Adenovirus
Ultrafiltration/ Concentration
Amine Kamen and Olivier Henry Development and optimization of an adenovirus production process, J Gene Med 6, S184S192, 2004
Page 28
0.1 M
0.25 M
0.35 M
1M
virus
time
0.5 M NaOH
Page 29
Purification strategy
process Cell lysis 60-70% Average Overall Recovery
75-95%
85-100%
Filter
Fractogel EMD DEAE 45-65%
Concentration
20-35%
SEC Polishing
15-30%
Adenovirus Type 5 (Ad5) chromatographic purification process at the 20 L scale; Arcand et al., BioProcessing Journal, Jan/Feb. 2003
Purified Ad5
Page 30
Purification of Alphavaccines
process Electroporation filtration on Sartopore 2 (0.45/2) Virus-like replicon particle (VRP) capture by AEX based operation
Formulation
Development and manufacture of alphavaccines; T. Talarico et al., BioProcessing Journal, Fall 2006
Page 31
Nuclease treatment Nuclease treatment after capture step after harvest Lsyate Capture chromatography Nuclease treatment PEG precipitation 36 % 1.8 >42.500 Lysate Nuclease treatment Capture chromatography PEG precipitation 57 % 5.0 >42.500
~8mL Bioreactor
~20L of Bioreactors
Simon Hsu: Case Study: Establishing a Benchmark for Economic Vaccine Scale-up Strategies MedImmune Vaccines, Inc., European BioPharm Scale-Up Congress 2008, 17-19 September 2008, Geneva, Switzerland Page 33
Purity (%)
Yield (VP, %)
Yield (IU, %)
VP/IU ratio
92 98
67 47 32
49 44 22
82 88
Blance et al (2000)
1013
81
99
Fractogel DEAE (M) PolyFlo 1014 input viral particles
40 73 84 55 75 94 57 90 97 54
25
Green et at (2002)
1. Anion exchange 2. Proprietary resin Final product 1. Anion exchange 2. Proprietary resin Final product
73 78 47
80
99
Viral particles (VP): measured by HPLC analytical anion-exchange assay; infectious units (IU): measured by tissue culture infectious dose (TCID50) assay; purity: determined by SDS-PAGE and Western blot analysis or by integration of HPLC chromatogram at 260 nm. (modified according to Burova & Ioffe, Gene Therapy 12, 2005
Page 35
Future trends?
Binding capacity 1000
100
IgG
pH
IgG
10
Salt
Protein titer: 0.2 10 mg/mL
1 Prot A
H. Graalfs
IEX
Max. Cap.
Chromatography mode
Page 13 36
Page 37
Thank you
Page 38